1	Interleukin-2	interleukin-2	_	_	_	_	_	_	_
2	promoter	promoter	_	_	_	_	_	_	_
3	activity	activity	_	_	_	_	_	_	_
4	in	in	_	_	_	_	_	_	_
5	Epstein-Barr	epstein-barr	_	_	_	_	_	_	_
6	virus-transformed	virus-transformed	_	_	_	_	_	_	_
7	B	B	_	_	_	_	_	_	_
8	lymphocytes	lymphocyte	_	_	_	_	_	_	_
9	is	be	_	_	_	_	_	_	_
10	controlled	control	_	_	_	_	_	_	_
11	by	by	_	_	_	_	_	_	_
12	nuclear	nuclear	_	_	_	_	_	_	_
13	factor-chi	factor-chi	_	_	_	_	_	_	_
14	B.	B.	_	_	_	_	_	_	_
15	The	the	_	_	_	_	_	_	_
16	regulation	regulation	_	_	_	_	_	_	_
17	of	of	_	_	_	_	_	_	_
18	interleukin	interleukin	_	_	_	_	_	_	_
19	(	(	_	_	_	_	_	_	_
20	IL)-2	il)-2	_	_	_	_	_	_	_
21	gene	gene	_	_	_	_	_	_	_
22	expression	expression	_	_	_	_	_	_	_
23	has	have	_	_	_	_	_	_	_
24	been	be	_	_	_	_	_	_	_
25	investigated	investigate	_	_	_	_	_	_	_
26	mainly	mainly	_	_	_	_	_	_	_
27	in	in	_	_	_	_	_	_	_
28	T	t	_	_	_	_	_	_	_
29	lymphocytes	lymphocyte	_	_	_	_	_	_	_
30	,	,	_	_	_	_	_	_	_
31	the	the	_	_	_	_	_	_	_
32	predominant	predominant	_	_	_	_	_	_	_
33	producers	producer	_	_	_	_	_	_	_
34	of	of	_	_	_	_	_	_	_
35	IL-2	il-2	_	_	_	_	_	_	_
36	.	.	_	_	_	_	_	_	_

1	However	however	_	_	_	_	_	_	_
2	,	,	_	_	_	_	_	_	_
3	B	B	_	_	_	_	_	_	_
4	cells	cell	_	_	_	_	_	_	_
5	can	can	_	_	_	_	_	_	_
6	also	also	_	_	_	_	_	_	_
7	synthesize	synthesize	_	_	_	_	_	_	_
8	IL-2	il-2	_	_	_	_	_	_	_
9	.	.	_	_	_	_	_	_	_

1	In	in	_	_	_	_	_	_	_
2	the	the	_	_	_	_	_	_	_
3	present	present	_	_	_	_	_	_	_
4	study	study	_	_	_	_	_	_	_
5	we	we	_	_	_	_	_	_	_
6	analyzed	analyze	_	_	_	_	_	_	_
7	the	the	_	_	_	_	_	_	_
8	control	control	_	_	_	_	_	_	_
9	of	of	_	_	_	_	_	_	_
10	IL-2	il-2	_	_	_	_	_	_	_
11	promoter	promoter	_	_	_	_	_	_	_
12	activity	activity	_	_	_	_	_	_	_
13	in	in	_	_	_	_	_	_	_
14	Epstein-Barr	epstein-barr	_	_	_	_	_	_	_
15	virus	virus	_	_	_	_	_	_	_
16	(	(	_	_	_	_	_	_	_
17	EBV)-transformed	ebv)-transformed	_	_	_	_	_	_	_
18	B	B	_	_	_	_	_	_	_
19	cell	cell	_	_	_	_	_	_	_
20	clones	clone	_	_	_	_	_	_	_
21	which	which	_	_	_	_	_	_	_
22	are	be	_	_	_	_	_	_	_
23	capable	capable	_	_	_	_	_	_	_
24	of	of	_	_	_	_	_	_	_
25	secreting	secrete	_	_	_	_	_	_	_
26	IL-2	il-2	_	_	_	_	_	_	_
27	at	at	_	_	_	_	_	_	_
28	a	a	_	_	_	_	_	_	_
29	low	low	_	_	_	_	_	_	_
30	level	level	_	_	_	_	_	_	_
31	after	after	_	_	_	_	_	_	_
32	stimulation	stimulation	_	_	_	_	_	_	_
33	with	with	_	_	_	_	_	_	_
34	phorbol	phorbol	_	_	_	_	_	_	_
35	12-myristate	12-myristate	_	_	_	_	_	_	_
36	13-acetate	13-acetate	_	_	_	_	_	_	_
37	and	and	_	_	_	_	_	_	_
38	the	the	_	_	_	_	_	_	_
39	Ca2+	ca2+	_	_	_	_	_	_	_
40	ionophore	ionophore	_	_	_	_	_	_	_
41	ionomycin	ionomycin	_	_	_	_	_	_	_
42	.	.	_	_	_	_	_	_	_

1	Transient	transient	_	_	_	_	_	_	_
2	transfections	transfection	_	_	_	_	_	_	_
3	using	use	_	_	_	_	_	_	_
4	reporter	reporter	_	_	_	_	_	_	_
5	constructs	construct	_	_	_	_	_	_	_
6	with	with	_	_	_	_	_	_	_
7	multiples	multiple	_	_	_	_	_	_	_
8	of	of	_	_	_	_	_	_	_
9	transcription	transcription	_	_	_	_	_	_	_
10	factor	factor	_	_	_	_	_	_	_
11	binding	binding	_	_	_	_	_	_	_
12	sites	site	_	_	_	_	_	_	_
13	from	from	_	_	_	_	_	_	_
14	the	the	_	_	_	_	_	_	_
15	IL-2	il-2	_	_	_	_	_	_	_
16	promoter	promoter	_	_	_	_	_	_	_
17	[	[	_	_	_	_	_	_	_
18	distal	distal	_	_	_	_	_	_	_
19	nuclear	nuclear	_	_	_	_	_	_	_
20	factor	factor	_	_	_	_	_	_	_
21	(	(	_	_	_	_	_	_	_
22	NF)-AT	NF)-AT	_	_	_	_	_	_	_
23	,	,	_	_	_	_	_	_	_
24	proximal	proximal	_	_	_	_	_	_	_
25	NF-AT	NF-AT	_	_	_	_	_	_	_
26	,	,	_	_	_	_	_	_	_
27	AP-1/Octamer	AP-1/Octamer	_	_	_	_	_	_	_
28	(	(	_	_	_	_	_	_	_
29	UPS	UPS	_	_	_	_	_	_	_
30	)	)	_	_	_	_	_	_	_
31	or	or	_	_	_	_	_	_	_
32	NF-chi	NF-chi	_	_	_	_	_	_	_
33	B	B	_	_	_	_	_	_	_
34	(	(	_	_	_	_	_	_	_
35	TCEd	TCEd	_	_	_	_	_	_	_
36	)	)	_	_	_	_	_	_	_
37	sites	site	_	_	_	_	_	_	_
38	]	]	_	_	_	_	_	_	_
39	were	be	_	_	_	_	_	_	_
40	performed	perform	_	_	_	_	_	_	_
41	.	.	_	_	_	_	_	_	_

1	In	in	_	_	_	_	_	_	_
2	EBV-transformed	ebv-transformed	_	_	_	_	_	_	_
3	B	B	_	_	_	_	_	_	_
4	clones	clone	_	_	_	_	_	_	_
5	,	,	_	_	_	_	_	_	_
6	the	the	_	_	_	_	_	_	_
7	chi	chi	_	_	_	_	_	_	_
8	B	B	_	_	_	_	_	_	_
9	site	site	_	_	_	_	_	_	_
10	exerted	exert	_	_	_	_	_	_	_
11	the	the	_	_	_	_	_	_	_
12	strongest	strong	_	_	_	_	_	_	_
13	inducible	inducible	_	_	_	_	_	_	_
14	activity	activity	_	_	_	_	_	_	_
15	;	;	_	_	_	_	_	_	_
16	the	the	_	_	_	_	_	_	_
17	NF-AT	nf-at	_	_	_	_	_	_	_
18	binding	binding	_	_	_	_	_	_	_
19	sites	site	_	_	_	_	_	_	_
20	showed	show	_	_	_	_	_	_	_
21	either	either	_	_	_	_	_	_	_
22	no	no	_	_	_	_	_	_	_
23	or	or	_	_	_	_	_	_	_
24	only	only	_	_	_	_	_	_	_
25	weak	weak	_	_	_	_	_	_	_
26	activity	activity	_	_	_	_	_	_	_
27	compared	compare	_	_	_	_	_	_	_
28	to	to	_	_	_	_	_	_	_
29	Jurkat	jurkat	_	_	_	_	_	_	_
30	T	t	_	_	_	_	_	_	_
31	cells	cell	_	_	_	_	_	_	_
32	.	.	_	_	_	_	_	_	_

1	An	an	_	_	_	_	_	_	_
2	IL-2	il-2	_	_	_	_	_	_	_
3	promoter	promoter	_	_	_	_	_	_	_
4	bearing	bear	_	_	_	_	_	_	_
5	a	a	_	_	_	_	_	_	_
6	defective	defective	_	_	_	_	_	_	_
7	NF-chi	NF-chi	_	_	_	_	_	_	_
8	B	B	_	_	_	_	_	_	_
9	site	site	_	_	_	_	_	_	_
10	was	be	_	_	_	_	_	_	_
11	completely	completely	_	_	_	_	_	_	_
12	inactive	inactive	_	_	_	_	_	_	_
13	in	in	_	_	_	_	_	_	_
14	EBV-transformed	ebv-transformed	_	_	_	_	_	_	_
15	B	B	_	_	_	_	_	_	_
16	cells	cell	_	_	_	_	_	_	_
17	,	,	_	_	_	_	_	_	_
18	while	while	_	_	_	_	_	_	_
19	it	it	_	_	_	_	_	_	_
20	still	still	_	_	_	_	_	_	_
21	had	have	_	_	_	_	_	_	_
22	activity	activity	_	_	_	_	_	_	_
23	in	in	_	_	_	_	_	_	_
24	Jurkat	Jurkat	_	_	_	_	_	_	_
25	T	t	_	_	_	_	_	_	_
26	cells	cell	_	_	_	_	_	_	_
27	.	.	_	_	_	_	_	_	_

1	In	in	_	_	_	_	_	_	_
2	seven	seven	_	_	_	_	_	_	_
3	EBV-B	ebv-b	_	_	_	_	_	_	_
4	cell	cell	_	_	_	_	_	_	_
5	clones	clone	_	_	_	_	_	_	_
6	or	or	_	_	_	_	_	_	_
7	lines	line	_	_	_	_	_	_	_
8	differing	differ	_	_	_	_	_	_	_
9	in	in	_	_	_	_	_	_	_
10	their	their	_	_	_	_	_	_	_
11	capacity	capacity	_	_	_	_	_	_	_
12	to	to	_	_	_	_	_	_	_
13	secrete	secrete	_	_	_	_	_	_	_
14	IL-2	il-2	_	_	_	_	_	_	_
15	,	,	_	_	_	_	_	_	_
16	the	the	_	_	_	_	_	_	_
17	activity	activity	_	_	_	_	_	_	_
18	of	of	_	_	_	_	_	_	_
19	the	the	_	_	_	_	_	_	_
20	IL-2	il-2	_	_	_	_	_	_	_
21	promoter	promoter	_	_	_	_	_	_	_
22	correlated	correlate	_	_	_	_	_	_	_
23	well	well	_	_	_	_	_	_	_
24	with	with	_	_	_	_	_	_	_
25	the	the	_	_	_	_	_	_	_
26	status	status	_	_	_	_	_	_	_
27	of	of	_	_	_	_	_	_	_
28	IL-2	il-2	_	_	_	_	_	_	_
29	secretion	secretion	_	_	_	_	_	_	_
30	.	.	_	_	_	_	_	_	_

1	Similarly	similarly	_	_	_	_	_	_	_
2	,	,	_	_	_	_	_	_	_
3	a	a	_	_	_	_	_	_	_
4	human	human	_	_	_	_	_	_	_
5	immunodeficiency	immunodeficiency	_	_	_	_	_	_	_
6	virus	virus	_	_	_	_	_	_	_
7	promoter	promoter	_	_	_	_	_	_	_
8	,	,	_	_	_	_	_	_	_
9	whose	whose	_	_	_	_	_	_	_
10	activity	activity	_	_	_	_	_	_	_
11	is	be	_	_	_	_	_	_	_
12	controlled	control	_	_	_	_	_	_	_
13	through	through	_	_	_	_	_	_	_
14	chi	chi	_	_	_	_	_	_	_
15	B	B	_	_	_	_	_	_	_
16	factors	factor	_	_	_	_	_	_	_
17	,	,	_	_	_	_	_	_	_
18	was	be	_	_	_	_	_	_	_
19	found	find	_	_	_	_	_	_	_
20	to	to	_	_	_	_	_	_	_
21	be	be	_	_	_	_	_	_	_
22	active	active	_	_	_	_	_	_	_
23	in	in	_	_	_	_	_	_	_
24	the	the	_	_	_	_	_	_	_
25	IL-2	il-2	_	_	_	_	_	_	_
26	producing	produce	_	_	_	_	_	_	_
27	EBV-B	ebv-b	_	_	_	_	_	_	_
28	cells	cell	_	_	_	_	_	_	_
29	,	,	_	_	_	_	_	_	_
30	but	but	_	_	_	_	_	_	_
31	inactive	inactive	_	_	_	_	_	_	_
32	in	in	_	_	_	_	_	_	_
33	the	the	_	_	_	_	_	_	_
34	non-IL-2-producing	non-il-2-producing	_	_	_	_	_	_	_
35	cells	cell	_	_	_	_	_	_	_
36	.	.	_	_	_	_	_	_	_

1	Electrophoretic	electrophoretic	_	_	_	_	_	_	_
2	mobility	mobility	_	_	_	_	_	_	_
3	shift	shift	_	_	_	_	_	_	_
4	assays	assay	_	_	_	_	_	_	_
5	using	use	_	_	_	_	_	_	_
6	protein	protein	_	_	_	_	_	_	_
7	extracts	extract	_	_	_	_	_	_	_
8	from	from	_	_	_	_	_	_	_
9	EBV-B	ebv-b	_	_	_	_	_	_	_
10	cells	cell	_	_	_	_	_	_	_
11	and	and	_	_	_	_	_	_	_
12	the	the	_	_	_	_	_	_	_
13	IL-2	IL-2	_	_	_	_	_	_	_
14	NF-chi	NF-chi	_	_	_	_	_	_	_
15	B	B	_	_	_	_	_	_	_
16	probe	probe	_	_	_	_	_	_	_
17	revealed	reveal	_	_	_	_	_	_	_
18	the	the	_	_	_	_	_	_	_
19	constitutive	constitutive	_	_	_	_	_	_	_
20	generation	generation	_	_	_	_	_	_	_
21	of	of	_	_	_	_	_	_	_
22	chi	chi	_	_	_	_	_	_	_
23	B	B	_	_	_	_	_	_	_
24	complexes	complex	_	_	_	_	_	_	_
25	in	in	_	_	_	_	_	_	_
26	IL-2-secreting	il-2-secreting	_	_	_	_	_	_	_
27	cells	cell	_	_	_	_	_	_	_
28	consisting	consist	_	_	_	_	_	_	_
29	mainly	mainly	_	_	_	_	_	_	_
30	of	of	_	_	_	_	_	_	_
31	heterodimeric	heterodimeric	_	_	_	_	_	_	_
32	p50/p65	p50/p65	_	_	_	_	_	_	_
33	complexes	complex	_	_	_	_	_	_	_
34	.	.	_	_	_	_	_	_	_

1	A	a	_	_	_	_	_	_	_
2	weaker	weak	_	_	_	_	_	_	_
3	chi	chi	_	_	_	_	_	_	_
4	B	B	_	_	_	_	_	_	_
5	complex	complex	_	_	_	_	_	_	_
6	formation	formation	_	_	_	_	_	_	_
7	and	and	_	_	_	_	_	_	_
8	faster-migrating	faster-migrating	_	_	_	_	_	_	_
9	complexes	complex	_	_	_	_	_	_	_
10	were	be	_	_	_	_	_	_	_
11	detected	detect	_	_	_	_	_	_	_
12	in	in	_	_	_	_	_	_	_
13	non-IL-2-secreting	non-il-2-secreting	_	_	_	_	_	_	_
14	cells	cell	_	_	_	_	_	_	_
15	.	.	_	_	_	_	_	_	_

1	These	these	_	_	_	_	_	_	_
2	results	result	_	_	_	_	_	_	_
3	demonstrate	demonstrate	_	_	_	_	_	_	_
4	that	that	_	_	_	_	_	_	_
5	the	the	_	_	_	_	_	_	_
6	IL-2	il-2	_	_	_	_	_	_	_
7	NF-chi	NF-chi	_	_	_	_	_	_	_
8	B	B	_	_	_	_	_	_	_
9	site	site	_	_	_	_	_	_	_
10	is	be	_	_	_	_	_	_	_
11	indispensable	indispensable	_	_	_	_	_	_	_
12	for	for	_	_	_	_	_	_	_
13	the	the	_	_	_	_	_	_	_
14	activity	activity	_	_	_	_	_	_	_
15	of	of	_	_	_	_	_	_	_
16	the	the	_	_	_	_	_	_	_
17	IL-2	il-2	_	_	_	_	_	_	_
18	promoter	promoter	_	_	_	_	_	_	_
19	in	in	_	_	_	_	_	_	_
20	EBV-transformed	ebv-transformed	_	_	_	_	_	_	_
21	B	B	_	_	_	_	_	_	_
22	cells	cell	_	_	_	_	_	_	_
23	,	,	_	_	_	_	_	_	_
24	whereas	whereas	_	_	_	_	_	_	_
25	other	other	_	_	_	_	_	_	_
26	transcription	transcription	_	_	_	_	_	_	_
27	factors	factor	_	_	_	_	_	_	_
28	appear	appear	_	_	_	_	_	_	_
29	to	to	_	_	_	_	_	_	_
30	be	be	_	_	_	_	_	_	_
31	less	less	_	_	_	_	_	_	_
32	important	important	_	_	_	_	_	_	_
33	for	for	_	_	_	_	_	_	_
34	IL-2	il-2	_	_	_	_	_	_	_
35	expression	expression	_	_	_	_	_	_	_
36	in	in	_	_	_	_	_	_	_
37	these	these	_	_	_	_	_	_	_
38	cells	cell	_	_	_	_	_	_	_
39	.	.	_	_	_	_	_	_	_

